U.S. markets close in 6 hours 24 minutes

Cue Biopharma, Inc. (CUE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
13.56-0.11 (-0.80%)
As of 9:35AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close13.67
Open13.01
Bid13.60 x 1100
Ask15.00 x 900
Day's Range13.40 - 13.67
52 Week Range10.69 - 31.69
Volume5,700
Avg. Volume508,467
Market Cap425.958M
Beta (5Y Monthly)1.81
PE Ratio (TTM)N/A
EPS (TTM)-1.50
Earnings DateMar 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Strength Seen in Cue Biopharma, Inc. (CUE): Can Its 27.7% Jump Turn into More Strength?
    Zacks

    Strength Seen in Cue Biopharma, Inc. (CUE): Can Its 27.7% Jump Turn into More Strength?

    Cue Biopharma, Inc. (CUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

  • Cue Biopharma's Stock Shoots Up After CUE-101 Shows Promise In Early-Stage Head & Neck Cancer Study
    Benzinga

    Cue Biopharma's Stock Shoots Up After CUE-101 Shows Promise In Early-Stage Head & Neck Cancer Study

    Cue Biopharma Inc (NASDAQ: CUE) has announced interim clinical data from its ongoing Phase 1a/1b monotherapy study of CUE-101 as second-line treatment for patients with human papilloma virus-positive recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC). Interim analysis highlights include: Confirmed partial response (PR) in one patient and stable disease (SD) in five patients, providing early signs of potential single-agent activity of CUE-101. Demonstrated evidence of both tumor-specific CD8+ T cell expansion and dose-dependent increases in NK cells in patients. Observed immune cell infiltration and tumor cell necrosis in patient tumor biopsies after CUE-101 treatment. Dose-proportional PK profile and comparable drug exposure levels in patients receiving repeated dosing cycles, consistent with a lack of drug-clearing anti-drug antibodies. No maximum tolerated dose was observed in patients dosed with up to 8 mg/kg of CUE-101. The company plans a potential selection of a recommended Phase 2 dose of CUE-101 by mid-2021 for further development as monotherapy in HPV+ R/M HNSCC. It also intends to report initial Phase 1 results from the combination study of CUE-101 with pembrolizumab in the second half of 2021 and initiate a Phase 2 neoadjuvant study with CUE-101 in the second half of 2021. Price Action: CUE is trading 30.6% higher at $14.71 during the market trading session on the last check Monday. See more from BenzingaClick here for options trades from BenzingaSoliton Stock Rallies After .60/Share Buyout From AbbVieDiffusion Pharma's Trans Sodium Crocetinate Associated With Improved Outcomes In COVID-19 Patients© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Cue Biopharma to Host Business Update Call and Webcast
    GlobeNewswire

    Cue Biopharma to Host Business Update Call and Webcast

    CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today it will host a conference call and webcast to provide a business update on Monday, May 17, 2021 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company’s website. Members of the Cue Biopharma executive management team will provide a clinical update from the Company’s ongoing Phase 1a/1b monotherapy dose escalation clinical trial of CUE-101, including discussing the confirmed partial response (PR) recently reported in one patient receiving CUE-101 as second-line treatment for HPV+ recurrent/metastatic head and neck squamous cell carcinoma. Management will also provide an update on the Company’s most recent technology platform developments and pipeline progress as well as updates on its strategic objectives and anticipated milestones. Webcast DetailsMonday, May 17, 2021 at 4:30 p.m. EDT Investors: 855-327-6837 International: 631-891-4304 Conference ID: 10014734 Webcast: http://public.viavid.com/index.php?id=144898 About Cue BiopharmaCue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body to transform the treatment of cancer, infectious disease and autoimmune disease. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) is designed to harness the body’s intrinsic immune system without the need for ex vivo manipulation. Headquartered in Cambridge, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.For more information, visit www.cuebiopharma.com and follow us on Twitter at https://twitter.com/CueBiopharma. Investor ContactGeorge B. Zavoico, Ph.D.VP, Investor Relations & Corporate Development Cue Biopharma, Inc. gzavoico@cuebio.com Media ContactDarren Opland, Ph.D.LifeSci Communicationsdarren@lifescicomms.com